How The Ingevity (NGVT) Investment Story Is Shifting As Analysts Rework Valuation Assumptions

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.

Analysts have lifted their price target for Ingevity to US$79.25, while keeping the model’s fair value output at US$79.25, signaling a stable core valuation framework. This change is tied to updated analyst commentary that weighs opportunity against execution risk, as models are refreshed around discount rates, long term revenue assumptions, and profit margins. As you read on, you will see how this evolving narrative could shape the way you track Ingevity’s story from here.

Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value Ingevity.

What Wall Street Has Been Saying

🐂 Bullish Takeaways

Wells Fargo lifted its price target for Ingevity by US$5, which signals greater conviction in the current valuation framework rather than a fundamental reset of expectations. The Wells Fargo commentary points to a view that the risk and reward profile remains acceptable, with updated assumptions around discount rates and profitability feeding into the higher target.

🐻 Bearish Takeaways

Even with the higher Wells Fargo target, the call still highlights execution risk, suggesting that investors may want to keep an eye on how closely future results align with these refreshed assumptions. The reliance on model tweaks, such as changes in long term revenue and margin inputs at Wells Fargo, underlines that small shifts in outlook can have a meaningful impact on valuation, which may keep some readers cautious.

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!NYSE:NGVT 1-Year Stock Price Chart

We've flagged 1 risk for Ingevity. See which could impact your investment.

What's in the News

Ingevity recorded long lived assets impairment charges of $109.3 million for the fourth quarter ended December 31, 2025, which will be reflected in reported earnings for that period. The company issued full year 2026 earnings guidance, with expected net sales in a range of $1.1b to $1.2b, providing a reference point for upcoming revenue levels. Between October 1, 2025 and December 31, 2025, Ingevity repurchased 615,736 shares for $30.89 million, completing a total buyback of 3,113,613 shares for $202.5 million under its August 2, 2022 program.

How This Changes the Fair Value For Ingevity

Fair value in the model remains at US$79.25, unchanged versus prior assumptions. Revenue growth input is effectively unchanged at about 105.56%. Net profit margin assumption stays essentially stable at about 17.05%. Future P/E multiple edges down slightly from about 15.15x to about 15.10x. The discount rate moves from 8.21% to about 8.10%.

Story Continues

Never Miss an Update: Follow The Narrative

Narratives link a company's business story to a financial forecast and fair value, so you can see how key events might shape the long term picture. They update as new data and commentary are added, giving you a living summary of what matters most.

Head over to the Simply Wall St Community and follow the Narrative on Ingevity to stay up to date on:

How the planned sale of lower margin businesses and focus on higher value specialty chemicals could affect margins, cash flow, and earnings resilience. The role of investment in engineered additives and EV battery materials, along with geographic expansion, in broadening Ingevity's end markets and revenue mix. Risks tied to APT segment weakness, tariff related demand pressure, portfolio reshaping, and competition that could affect future revenue and margin stability.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NGVT.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments